Eli Lilly and Company's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
Posted:
FDA has authorized bebtelovimab for emergency use for certain non-hospitalized patients with mild-to-moderate COVID-19 at high risk of progression to severe disease for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate Bebtelovimab neutralizes Omicron as demonstrated by pseudovirus and authentic virus data.
In an NHS survey of 303 senior doctors, 60 per cent said they would be interested in working for the online service, alongside their existing roles, when it starts next year.
Read more here.
The UCL Centre for Digital Public Health in Emergencies (dPHE) has been designated a World Health Organisation (WHO) Collaborating Centre for Digital Public Health and Pandemic Preparedness.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us